Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL21P5 is a non-coding pseudogene in the human genome that shares sequence similarity with the gene encoding ribosomal protein L21 (RPL21)[4]. Pseudogenes such as RPL21P5 do not encode functional proteins and have no established biological or therapeutic role. They are remnants of gene duplication or retrotransposition events, often containing sequence mutations or lacking regulatory elements necessary for gene expression. No evidence links RPL21P5 to any protein production, disease association, or drug interaction, and it is not considered a therapeutic target[4]. RPL21P5 is a pseudogene and not an active target or protein. It should not be considered a therapeutic, biological, or mechanistic target in scientific or pharmaceutical contexts.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L21 pseudogene 5 (RPL21P5).